(Q84069164)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

Lee Campbell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Rosa Nuttall

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

David Griffiths

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

3457-3467

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Kidney cancer: past, present, and future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Molecular markers for predicting prognosis of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Integrated therapy of kidney cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

The role of targeted therapy in metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Metastatic non-clear cell renal cell carcinoma: current therapeutic options

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Targeted therapies for kidney cancer in urologic practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Prognostic factors in renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

MAP kinase signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Oncogenic Ras in tumour progression and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Role of MAP kinase in tumor progression and invasion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Protein kinases as drug targets in cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

The Heidelberg classification of renal cell tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Contribution of grade, vascular invasion and age to outcome in clinically localized renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Phosphorylation of ERK1/2 and prognosis of clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Using protein expressions to predict survival in clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24389

7 January 2021

Identifiers

DOI

10.1002/CNCR.24389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19526593%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference